China Pharma Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Form 10-Q Filing | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly983.5K
Quarterly Net Loss Quarterly-1.1M
Cash and Cash Equivalents Quarterly168.5K
Working Capital Deficit Quarterly-5.3M
Watch Items
- Going Concern StatusTrigger: Inability to secure additional financing or related-party loansAction: Monitor management's efforts to refinance short-term debt and secure additional funding from the Chairperson and her spouse.
- NYSE American Listing ComplianceTrigger: Stock price falling below minimum listing requirements or failure to maintain minimum stockholders' equityAction: Track potential implementation of another reverse stock split under the authorized 1-for-20 ratio approved by shareholders.
- Commercialization of Dry Eye Disease Therapeutic DeviceTrigger: NMPA market launch approval and initial sales volumeAction: Evaluate if the newly acquired patents and medical devices translate into high-margin revenue streams to offset generic drug competition.
Research as of 20 Jun 2026